Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

Pharma Tech

Boehringer signs oncology deal with Sino Biopharm worth up to $7.4bn

Nov 4, 2026, 11:39 AM

Read Full Article → Boehringer signs oncology deal with Sino Biopharm worth up to $7.4bn

Boehringer signs oncology deal with Sino Biopharm worth up to $7.4bn

Translate article text

Choose a language and wait for the translated text.

The collaboration will focus on antibody-drug conjugate (ADC) and T-cell engager (TCE) technologies across six programmes.

Boehringer signs oncology deal with Sino Biopharm worth up to $7.4bn | PharmaVoice